Presidio Partners 2007 Form 3 Neos Therapeutics / David J Collier ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Presidio Partners 2007, L.P.

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/22/2015

3. Issuer Name and Ticker or Trading Symbol
Neos Therapeutics, Inc. [ NEOS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Redeemable Preferred Stock, $0.001 par value	(1)	(1)	Common Stock	406,250	(1)	D
Series C Redeemable Preferred Stock, $0.001 par value	(1)	(1)	Common Stock	677,622	(1)	D
Preferred Stock Warrant (Right to Buy)	(2)	01/30/2018	Series C Convertible Preferred Stock	390,000(2)	5(2)	D
Series B Redeemable Preferred Stock, $0.001 par value	(1)	(1)	Common Stock	10,416	(1)	I	By: Presidio Partners 2007 (Parallel), L.P.
Series C Redeemable Preferred Stock, $0.001 par value	(1)	(1)	Common Stock	17,374	(1)	I	By: Presidio Partners 2007 (Parallel), L.P.
Preferred Stock Warrant (Right to Buy)	(2)	01/30/2018	Series C Convertible Preferred Stock	10,000(2)	5(2)	I	By: Presidio Partners 2007 (Parallel), L.P.

1. Name and Address of Reporting Person^*

Presidio Partners 2007, L.P.

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Presidio Partners 2007 (Parallel), L.P.

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Presidio Partners 2007 GP, L.P.

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Presidio Partners 2007 GP, LLC

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Watson James F

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Sohail Faysal A.

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Collier David J

(Last) (First) (Middle)

ONE LETTERMAN DRIVE

BUILDING C, SUITE CM500

(Street)

SAN FRANCISCO CA 94129

(City) (State) (Zip)

Explanation of Responses:

1. Each share of the issuer's Series B Preferred Stock and Series C Preferred Stock will be automatically converted on a 2.4 for 1 basis into common stock immediately prior to the closing of the issuer's initial public offering and has no expiration.

2. The warrant is exercisable at the earlier of (i) the holder's election for the number of shares of Series C preferred stock (a) shown in column 3 at a price of $5.00 per share of Series C preferred stock or (b) such number of shares issuable pursuant to a cashless net exercise provision pursuant to which the holder surrenders the warrant and recieves a net number of shares of Series C preferred stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price (the "Cashless Exercise Provision"); and (ii) immediately prior to the closing of the Issuer's initial public offering pursuant to the Cashless Exercise Provision.

Remarks:

	PRESIDIO PARTNERS 2007, L.P. By: Presidio Partners 2007 GP, L.P., its General Partner By: Presidio Partners 2007 GP LLC, its General Partner /s/ David J. Collier, Manager	07/22/2015
	Presidio Partners 2007 (Parallel), L.P., By: /s/ David J. Collier, Manager	07/22/2015
	Presidio Partners 2007 GP, L.P. /s/ David J. Collier, Manager	07/22/2015
	Presidio Partners 2007 GP, LLC /s/ David J. Collier, Manager	07/22/2015
	/s/ James F. Watson	07/22/2015
	/s/ Faysal A. Sohail	07/22/2015
	/s/ David J. Collier	07/22/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.